Firebrick Pharma Limited (ASX:FRE) has disclosed a change in the relevant interests of director Al Moghaddam, following the acquisition of 3,000,000 unlisted options on 16 November 2026, as detailed in a Change of Director's Interest Notice lodged with the ASX.
Key Points
- Director Al Moghaddam acquired 3,000,000 unlisted options expiring 16 November 2031 at an exercise price of $0.06, with nil consideration paid.
- The options were approved by members at the company's AGM held on 11 November 2026.
- Following the change, Al Moghaddam holds 1,000,000 unlisted options expiring 10 February 2030 at $0.15, and 3,000,000 unlisted options expiring 16 November 2031 at $0.06.
- The interest is held directly and was not traded during a closed period.
Options Acquisition by Director Al Moghaddam
According to the filing, director Al Moghaddam acquired 3,000,000 unlisted options in Firebrick Pharma Limited on 16 November 2026. The options carry an exercise price of $0.06 each and expire on 16 November 2031. The consideration for the acquisition was nil. The filing records that prior to this change, Al Moghaddam held 1,000,000 unlisted options expiring 10 February 2030 at an exercise price of $0.15. The nature of the change is recorded as a direct interest, with no indirect interests or registered holders noted in the filing.
AGM Approval of Option Issue
The filing states that the acquisition arose from approval granted by members of Firebrick Pharma Limited at the company's Annual General Meeting held on 11 November 2026. The options were issued under this member approval, with the change of interest date recorded as 16 November 2026. The filing confirms the securities were not traded during a closed period and that no prior written clearance was required or sought in connection with the transaction. No contractual interests were disclosed in Part 2 of the notice, with all contract-related fields recorded as not applicable.
Director's Holdings Following the Change
Following the change disclosed in the notice, Al Moghaddam's total direct holdings in Firebrick Pharma Limited comprise two separate tranches of unlisted options. The first tranche consists of 1,000,000 unlisted options expiring 10 February 2030 with an exercise price of $0.15, which were held prior to the current change. The second tranche consists of the newly acquired 3,000,000 unlisted options expiring 16 November 2031 at $0.06. The filing notes the previous Change of Director's Interest Notice for Al Moghaddam was dated 2 March 2026. No securities were disposed of as part of this transaction.



Please wait processing your request...